Understanding MASH

MASH is defined by a specific trio of findings on liver biopsy: fat in the liver cells (steatosis), active inflammation, and a particular pattern of cell injury called hepatocyte ballooning. Each of these components contributes to the disease's ability to cause lasting harm.

The ballooning pattern is especially important to understand. Hepatocyte ballooning represents liver cells that are swollen and damaged, often on the verge of dying. When these cells die, they release their contents into the surrounding tissue, triggering further immune activation and creating a self-sustaining cycle of injury and inflammation.

These numbers make MASH one of the most consequential chronic diseases of our era, yet it remains underdiagnosed and undertreated.

What the Research Shows

Phase 2 Foundation: Semaglutide in Biopsy-Confirmed NASH

The clinical case for Wegovy in MASH builds on the phase 2 trial by Newsome and colleagues, which tested a daily subcutaneous formulation of semaglutide at various doses. The 0.4 mg daily dose, which delivers a similar total weekly exposure to the 2.4 mg weekly Wegovy dose, produced the best liver outcomes.

The NAS score is a standardized histological grading system used by pathologists to quantify the severity of MASH on biopsy.

The ESSENCE Phase 3 Program

Novo Nordisk's ESSENCE trial represents the pivotal step toward potential FDA approval of semaglutide for MASH. This large, multicenter study tests semaglutide 2.4 mg weekly (the Wegovy dose and schedule) in patients with biopsy-proven MASH and fibrosis stages F2 or F3.

Having two co-primary endpoints means that the trial can demonstrate benefit on both inflammation and fibrosis independently.

Weight Loss as the Foundation

A crucial advantage of Wegovy in the MASH context is the magnitude of weight loss it produces. The STEP trial program established that semaglutide 2.4 mg produces average weight loss of 15-17% over 68 weeks in patients with obesity. For MASH, this matters enormously because liver outcomes track closely with weight loss.

Wegovy consistently pushes patients past this threshold, which no previous weight loss medication could reliably achieve.

How Wegovy May Help

Wegovy delivers semaglutide at 2.4 mg once weekly, the highest approved dose of this GLP-1 receptor agonist. For MASH, the therapeutic rationale centers on three pillars.

First, substantial weight loss reduces the metabolic overload that drives hepatic steatosis. As patients lose weight, less fat arrives at the liver from shrinking adipose stores, and the liver itself produces less new fat due to improved insulin sensitivity.

Second, reduced hepatic fat means reduced lipotoxicity, which is the primary trigger for MASH inflammation. As the toxic fat burden decreases, the inflammatory cascade quiets down, hepatocyte ballooning resolves, and the stimulus for fibrogenesis is removed.

Third, there may be direct anti-inflammatory effects of GLP-1 receptor activation in the liver that supplement the weight-mediated benefits.

Important Safety Information

Wegovy carries a boxed warning for thyroid C-cell tumors observed in rodent studies. It is contraindicated in patients with medullary thyroid carcinoma or MEN 2 syndrome.

GI side effects were common in STEP trials: nausea (44%), diarrhea (30%), vomiting (24%), and constipation (24%). For MASH patients, who may have altered GI motility related to their liver condition or portal hypertension, these effects require careful attention. Most patients found symptoms manageable with the 16-20 week dose escalation protocol.

Gallbladder disease is a particular concern. In the STEP 1 trial, cholelithiasis (gallstones) occurred in 2.6% of Wegovy-treated patients versus 1.2% on placebo. For MASH patients, who already have metabolic risk factors for gallstone formation, this elevated risk warrants proactive discussion.

Pancreatitis, kidney injury from dehydration, and hypoglycemia with concurrent insulin or sulfonylureas are additional risks to monitor. Wegovy is approved for chronic weight management but not yet for MASH specifically.

Who Might Benefit

Wegovy is best suited for MASH patients who also meet the weight management indication: BMI of 30 or above, or 27 or above with a weight-related health condition. Since MASH itself qualifies as a weight-related condition, many MASH patients will meet these criteria.

The medication may be especially appropriate for patients with MASH and fibrosis stages F1-F3 who need aggressive metabolic intervention, those with MASH who do not have type 2 diabetes (since Wegovy's weight management indication applies regardless of diabetes status), and patients who have plateaued with lifestyle efforts and need pharmacological support to reach the weight loss thresholds associated with MASH resolution.

How to Talk to Your Doctor

If MASH is part of your health picture, consider bringing up these points at your next visit:

• Ask whether the ESSENCE trial results are available yet and what they mean for your treatment options
• Discuss whether Wegovy could help you reach the 10-15% weight loss range where MASH resolution becomes likely
• Ask about baseline liver assessments, including non-invasive fibrosis tests, before starting treatment
• Talk about the monitoring schedule: how often should liver enzymes, imaging, or other assessments be repeated?
• Discuss the timeline: how long should you try the medication before deciding if it is working for your liver?

Having both a weight management provider and a hepatologist involved in your care ensures no aspect of your condition is overlooked.

Frequently Asked Questions

Is Wegovy the same drug studied in the semaglutide MASH trials?

The phase 2 trial used a daily subcutaneous formulation at 0.4 mg, which is not commercially available. However, the phase 3 ESSENCE trial uses semaglutide 2.4 mg weekly, which is the same dose and schedule as Wegovy. So yes, the ESSENCE trial is studying what is essentially the Wegovy product for MASH.

If I lose weight on Wegovy and my MASH resolves, can I stop the medication?

This is one of the key unanswered questions. STEP 4 trial data showed that patients who switched from semaglutide to placebo regained weight and lost metabolic improvements. The same pattern would likely apply to liver outcomes. Ongoing treatment or permanent lifestyle changes may be necessary to maintain MASH resolution. Discuss a long-term plan with your care team.

Can Wegovy help if I already have cirrhosis from MASH?

Patients with established cirrhosis were largely excluded from clinical trials, so data is limited. Compensated cirrhosis (where the liver still functions adequately) might benefit, but decompensated cirrhosis (with complications like ascites or variceal bleeding) requires specialized hepatology management. Do not start Wegovy for advanced liver disease without input from a liver specialist.

How does Wegovy compare to resmetirom (Rezdiffra) for MASH?

Resmetirom is the first FDA-approved medication specifically for MASH with moderate to advanced fibrosis. It works through a completely different mechanism (thyroid hormone receptor beta agonism) and targets liver-specific pathways. Wegovy works through weight loss and metabolic improvement. In the future, combining these approaches may offer even better outcomes than either alone. Your hepatologist can advise on which therapy, or combination, makes the most sense for you.

Take the Next Step With Form Blends

At Form Blends, we believe that weight management is about more than appearance. It is about protecting your organs, including your liver, from the damage that metabolic dysfunction can cause. Our telehealth providers can help you explore whether Wegovy is the right tool for your weight and metabolic health goals. Reach out today to start the conversation.